Robust sealing of blood vessels with cholesteryl group-modified, Alaska pollock-derived gelatin-based biodegradable sealant under wet conditions
Robust sealing of blood vessels with cholesteryl group-modified, Alaska pollock-derived gelatin-based biodegradable sealant under wet conditions
复制标题
在潮湿条件下,使用胆固醇基团改性、阿拉斯加鳕鱼衍生的明胶基可生物降解密封剂牢固密封血管
DOI:
10.1166/jbn.2016.2210
复制
发表时间:
2016
影响因子:
2.9
通讯作者:
K.; Kajiyama
中科院分区:
文献类型:
--
作者:
Tetsushi T.; Mizuta;R.; Ito;T.; Yoshizawa;K.; Kajiyama
A novel surgical sealant was developed by partially modifying the amino groups of Alaska pollock-derived gelatin derivative with cholesteryl groups (Chol-apGltn), which was combined with the crosslinker, pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate (4S-PEG). The burst strength of the resultant sealant was tested using fresh porcine aorta as an adherend. The Chol-apGltn/4S-PEG sealant cured within 25.4 ± 2.0 s. Burst strength increased with increasing degree of Chol modification up to a maximum value of 8.3 mol% (8.3Chol-apGltn). The highest burst strength of the 8.3Chol-apGltn/4S-PEG sealant was 341.3 ± 77.5 mmHg, which was 3.5- and 11.6-fold higher than that of the original apGltn/4S-PEG and commercial fibrin sealants, respectively. The 8.3Chol-apGltn/4S-PEG sealant swelled only slightly in solution (1.1-fold as compared to commercially prepared sealant). Furthermore, tissue migration into the 8.3Chol-apGltn/4S-PEG sealant and subsequent biodegradation was observed following implantation for 4–8 weeks. These results suggest that the 8.3Chol-apGltn/4S-PEG sealant has biomedical applications, including use in cardiovascular and thoracic surgery.